» Articles » PMID: 26917013

The Oncogenic Triangle of HMGA2, LIN28B and IGF2BP1 Antagonizes Tumor-suppressive Actions of the Let-7 Family

Overview
Specialty Biochemistry
Date 2016 Feb 27
PMID 26917013
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor-suppressive let-7 microRNA family targets various oncogene-encoding mRNAs. We identify the let-7 targets HMGA2, LIN28B and IGF2BP1 to form a let-7 antagonizing self-promoting oncogenic triangle. Surprisingly, 3'-end processing of IGF2BP1 mRNAs is unaltered in aggressive cancers and tumor-derived cells although IGF2BP1 synthesis was proposed to escape let-7 attack by APA-dependent (alternative polyadenylation) 3' UTR shortening. However, the expression of the triangle factors is inversely correlated with let-7 levels and promoted by LIN28B impairing let-7 biogenesis. Moreover, IGF2BP1 enhances the expression of all triangle factors by recruiting the respective mRNAs in mRNPs lacking AGO proteins and let-7 miRNAs. This indicates that the downregulation of let-7, largely facilitated by LIN28B upregulation, and the protection of let-7 target mRNAs by IGF2BP1-directed shielding in mRNPs synergize in enhancing the expression of triangle factors. The oncogenic potential of this triangle was confirmed in ovarian cancer (OC)-derived ES-2 cells transduced with let-7 targeting decoys. In these, the depletion of HMGA2 only diminishes tumor cell growth under permissive conditions. The depletion of LIN28B and more prominently IGF2BP1 severely impairs tumor cell viability, self-renewal and 2D as well as 3D migration. In conclusion, this suggests the targeting of the HMGA2-LIN28B-IGF2BP1 triangle as a promising strategy in cancer treatment.

Citing Articles

A pan-cancer analysis reveals the oncogenic and immunological role of insulin-like growth factor 2 mRNA-binding protein family members.

Zeng F, Chen L, Li J, Yu W, Sa N, Zhang K Discov Oncol. 2025; 16(1):323.

PMID: 40088376 DOI: 10.1007/s12672-025-02077-2.


The IGF2BP1 oncogene is a druggable mA-dependent enhancer of YAP1-driven gene expression in ovarian cancer.

Schott A, Simon T, Muller S, Rausch A, Busch B, Glass M NAR Cancer. 2025; 7(1):zcaf006.

PMID: 40008228 PMC: 11850222. DOI: 10.1093/narcan/zcaf006.


The pivotal role of ZNF384: driving the malignant behavior of serous ovarian cancer cells via the LIN28B/UBD axis.

Yang Y, He R, Li D, Mu T, Kuang Z, Wang M Cell Biol Toxicol. 2024; 40(1):100.

PMID: 39562372 PMC: 11576860. DOI: 10.1007/s10565-024-09938-6.


The role of high mobility group proteins in cellular senescence mechanisms.

Chen J, Li H, Huang Y, Tang Q Front Aging. 2024; 5:1486281.

PMID: 39507236 PMC: 11537863. DOI: 10.3389/fragi.2024.1486281.


Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer.

Williams M, Howard D, Donnelly C, Izadi F, Parra J, Pugh M Cell Commun Signal. 2024; 22(1):443.

PMID: 39285292 PMC: 11404028. DOI: 10.1186/s12964-024-01806-4.


References
1.
Anglesio M, Arnold J, George J, Tinker A, Tothill R, Waddell N . Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res. 2008; 6(11):1678-90. PMC: 6953412. DOI: 10.1158/1541-7786.MCR-08-0193. View

2.
Zirkel A, Lederer M, Stohr N, Pazaitis N, Huttelmaier S . IGF2BP1 promotes mesenchymal cell properties and migration of tumor-derived cells by enhancing the expression of LEF1 and SNAI2 (SLUG). Nucleic Acids Res. 2013; 41(13):6618-36. PMC: 3711427. DOI: 10.1093/nar/gkt410. View

3.
Goswami S, Tarapore R, TeSlaa J, Grinblat Y, Setaluri V, Spiegelman V . MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor mRNA is inhibited by the coding region determinant-binding protein. J Biol Chem. 2010; 285(27):20532-40. PMC: 2898355. DOI: 10.1074/jbc.M110.109298. View

4.
Davidson B, Rosenfeld Y, Holth A, Hellesylt E, Trope C, Reich R . VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. Hum Pathol. 2014; 45(7):1520-8. DOI: 10.1016/j.humpath.2014.03.005. View

5.
Zhu Q, Wong A, Krishnan A, Aure M, Tadych A, Zhang R . Targeted exploration and analysis of large cross-platform human transcriptomic compendia. Nat Methods. 2015; 12(3):211-4, 3 p following 214. PMC: 4768301. DOI: 10.1038/nmeth.3249. View